R
33.81
-0.23 (-0.68%)
| 前收盘价格 | 34.04 |
| 收盘价格 | 33.84 |
| 成交量 | 1,705,371 |
| 平均成交量 (3个月) | 509,348 |
| 市值 | 936,904,640 |
| 价格/销量 (P/S) | 411.22 |
| 股市价格/股市净资产 (P/B) | 11.05 |
| 52周波幅 | |
| 利润日期 | 6 Nov 2025 |
| 稀释每股收益 (EPS TTM) | -19.84 |
| 总债务/股东权益 (D/E MRQ) | 2.16% |
| 流动比率 (MRQ) | 21.11 |
| 营业现金流 (OCF TTM) | -108.63 M |
| 杠杆自由现金流 (LFCF TTM) | -65.95 M |
| 资产报酬率 (ROA TTM) | -44.72% |
| 股东权益报酬率 (ROE TTM) | -75.60% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | RAPT Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
0.2
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.0 |
| 平均 | 0.17 |
|
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 0.42% |
| 机构持股比例 | 99.41% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合